Dr. Paz-Ares (MD, Ph.D.) is currently Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at National Oncology Research Center, all in Madrid.He graduated with a degree in Medicine from the Universidad Autónoma de Madrid, in 1986, and was trained as a resident in Medical Oncology at Hospital 12 de Octubre (1988-2001). In 1993, he completed a Ph.D. in Medicine at the Universidad Autónoma de Madrid. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, (1993– 1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995. Before the current position he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014), Head of the Pharmacology Unit and responsible for Early Clinical Studies of Thoracic and Genitourinary Tumours at the University Hospital "12 de Octubre" in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).Luis Paz-Ares’s research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 340 articles in peer review journals including New England Journal of Medicine, Lancet, Lancet Oncology, Nature Medicine, Journal of Clinical Oncology and many others. He has served as a member of several committees, including ASCO and ESMO meeting Scientific Committees, European Organisation for Research and Treatment of Cancer Protocol Review Committee and Audit Committee, the Spanish Agency of Medicines and Medical Devices and the European Medicines Agency. He is the Chief Medical Officer of the AECC where he also seats at the Board.

Prof. Giorgio Scagliotti joined the IASLC Board of Directors in 2015, serving as its president-elect and then president from 2015-2019. As Editor, he helped created the IASLC reference book, Thoracic Oncology: The IASLC Multidisciplinary Approach. Professor of Medical Oncology at Italy’s University of Turin School of Medicine, Dr. Scagliotti is also Chief of Medical Oncology at Turin’s San Luigi Gonzaga Hospital’s Division of Thoracic Oncology. He serves as a member of the administrative board of the University of Torino as well. Prior to his role as Chief of Medical Oncology, Dr. Scagliotti acted as the Head of the Department of Oncology of the University of Torino and served as the Chairperson of the Postgraduate School in Respiratory Medicine. Professor Scagliotti focuses his research on translational research and targeted molecular therapies for lung cancer. He is principal investigator in European and international clinical trials, including investigator-initiated studies, and is study coordinator for several trials. He has authored or co-authored more than 300 papers in peer-reviewed journals. Professor Scagliotti earned his medical degree and completed his postgraduate training in respiratory medicine, internal medicine and medical oncology at the University of Turin.

Prof. Shun LU, MD, is currently head of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University. He served as the leading PI for more than 20 multi-center Phase III oncology clinical trials and participated as the key contributor for more than 50 global and regional clinical trials as well. He has authored more than 200 peer-reviewed articles, many of which has published at JCO, Annuals of Oncology, Clinical Cancer Research, Chest and JTO etc. Dr. LU currently serves as associate editor for Journal of Thoracic Oncology and Lung Cancer, editor for The Oncologist. Dr. Lu is the advisory board member for Center for Drug Evaluation at NMPA. He is also the chair of Chinese Lung Cancer Association and executive director of CSCO. Dr. LU’s other appointments includes the chair of Oncology Society of Shanghai Medical Association, Chair of Lung Cancer Sub-committee at Oncology Society of Chinese Medical Association, and vice president of the Oncology Branch of Shanghai Medical Doctor Association.

Dr. Yasushi Goto is currently the Assistant chief, Division of Thoracic Oncology, of National Cancer Center (NCC) Hospital, Tokyo. He received his medical degree and doctorate degree in University of Tokyo. He has been working for National Cancer Center Hospital, Tokyo since 2014. His current main researches are medical oncology (thoracic malignancies) and translational medicine. He has engaged in more than 50 scientific papers including Journal of Thoracic Oncology, Journal of Clinical Oncology and Lancet. He is a member of steering committee in several global and domestic studies, and the primary investigators of JCOG trial which is evaluating the efficacy of discontinuing PD-L1 axis inhibitors, and others. He is also a staff in Section of Knowledge Integration of Center for Cancer Genomics and Advanced Therapeutics and Rare Cancer Center, director of patient supportive organizations, secretary general of JSMO (Japanese Society of Medical Oncology), panel member of guideline and database committee in Japanese Lung Cancer Society, associate editor of Japanese Journal of Clinical Oncology and communication committee member of IASLC (International Association for the Study of Lung Cancer).

Director, Institute of Drug Clinical Trial and Clinical Pharmacology, West China Hospital Professor, Department of Thoracic Oncology, Cancer Center; and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University

Dr. Hye Ryun Kim is associate professor in the Division of Medical Oncology in Yonsei Cancer Center. She graduated from Yonsei University College of Medicine and trained for Residency and Clinical Fellowship in Internal Medicine and Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine. She has focused on the study and development of novel therapeutic agents and modalities in lung cancer and head and neck cancer though clinical trials. Research interests are identification of resistance mechanism to targeted therapy and determinants for tumor-immune microenvironment in lung cancer patients. She leads several clinical trials including investigator-initiated studies focusing on novel approaches for treating these diseases.
Dr. Hye Ryun Kim served as Vice Chief of Lung Cancer Center in Yonsei Cancer Center. She has been a general affair in Lung Cancer Committee and an active member of Korean Cancer Study Group (KCSG). She served as a member of Editorial Board of Yonsei Medical Journal.
Dr. Hye Ryun Kim has been the recipient of several National Research Fund and industry funded grants studying lung cancer and head and neck cancer. Her research interests include immune profiling to identify predictive determinants and hyperprogression for immunotherapy using flow cytometer and genomics and acquired resistant mechanism for targeted therapy in oncogene driven lung cancer patients. She has received funding from the National Research Fund regarding Single-cell multiomics of tumor microenvironment. Dr. Hye Ryun Kim has published more than 100 articles in peer-reviewed journals.
Representative publications

1. Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade JCI Insight. 2020 (Correspondence)
2. Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC Cancer Discov. 2020
3. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer Clin Cancer Res. 2020 (Correspondence)
4. The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression Cancer Res. 2020 (Correspondence)
5. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019 (Correspondence)
6. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. J Immunother Cancer. 2019 (First author)
7. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018 (Co-author)
8. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol. 2017 (Co-first author)
9. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol. 2017 (First author)
10. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial J Clin Oncol. 2020 (Co-author)
11. Tumor-Infiltrating Regulatory T Cell Accumulation in the Tumor Microenvironment is Mediated by IL33/ST2 Signaling Cancer Immunol Res 2020 (Co-author)

Keunchil Park is Professor of the Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Professor Park had served as Chair of the Lung Cancer Committee of the Korean Cancer Study Group (KCSG) and also served as Chairman of the Board of Directors, Korean Association for Clinical Oncology (KACO). He has been involved in many IASLC activities since 1996, including Scientific Secretary of the 12th World Conference on Lung Cancer (WCLC; Sept, 2007), and President of the 4th Asia Pacific Lung Cancer Conference (Dec, 2010). He also served the IASLC as the Board of Directors since 2009 to 2013. More recently Prof. Park served as Co-President with Prof. Hisao Asamura of the 18th WCLC, Oct 15-18, 2017, Yokohama, Japan. He received the Merit Award of IASLC in 2016. Prof. Park is also actively engaged in ASCO as a member of the International Education Steering Group and leads the ASCO Asia Pacific Regional Council as Chair. He also served as Chair of the Korea Actionable Genome Consortium 2015-2018 and the Scientific Co-Chair for ESMO-Asia 2017. Prof. Park is a member of the ICGC Scientific Steering Committee since 2013 and served as Organizing Chairman of the 13th ICGC workshop, June 12-14, 2017 in Seoul, Korea. He was nominated as Steering Committee member of ICGC-ARGO and recently appointed as Member of the Management Committee.

Dr. Ahn is a board-certified medical oncologist and associate professor at Gachon University Gil Medical Center, Incheon, Korea, with a practice dedicated to the treatment of patients with lung cancer, breast cancer, and head and neck cancers.

EDUCATION, POSTDOCTAL TRAINING, ACADEMIC APPOINTMENT 2000-2006: Kyoto University School of Medicine, M.D., Kyoto, Japan 2011-2012: Assistant Professor, Department of Multidisciplinary Cancer Treatment, Graduate School of Medicine and Faculty of Medicine Kyoto University, Kyoto, Japan 2012-2015: Graduate School of Medicine, Kindai University, Ph.D., Osaka, Japan 2014-2015: Research Fellowship for Young Scientist, Japan Society for the Promotion of Science (DC2) 2015-2016: Assistant Professor, Department of Genome Biology, Kindai University, Osaka, Japan. 2016-2019: Researcher, Division of Cancer Immunology, National Cancer Center, Chiba, Japan 2017-2018: Research Fellowship for Young Scientist, Japan Society for the Promotion of Science (PD) 2019-present: Division Head, Chiba Cancer Center, Research Institute SPECIALITY and FIELD of INTEREST Pulmonary Medicine, Translational Research, Cancer Immunology and Genome Biology